|
|
 |
|
Viewing report
|
|
|
|
Bulletin: Valeant Pharmaceuticals International Inc. Ratings, Outlook Not Affected By Recent Acquisition Announcements Aug 11
Standard & Poors, Aug 2011
Abstract
BOSTON (Standard & Poor's) Aug. 5, 2011--Standard & Poor's Ratings Services said today that its BB-/Stable/-- corporate credit rating on Mississauga, Ontario-based Valeant Pharmaceuticals International Inc. is unchanged following recent announcements that it will acquire Sanitas Group, Dermik, and Ortho Dermatologics in three separate transactions. This follows our expectation that, on a pro forma basis, any debt incurred to fund these acquisitions, which aggregate approximately $1.3 billion, will keep leverage below the company's stated target of 4x....
Companies mentioned in this report are: Valeant Pharmaceuticals International Inc.
Action: Bulletin
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.
|
|
|
|
